Walvax Biotechnology Co., Ltd.
Walvax Biotechnology is a Chinese biotechnology company specializing in vaccine research, product development, manufacturing and commercialization. Its activities span immunization products and investigation of vaccine technologies for the prevention of infectious disease. The company operates an industrial and research platform in China and maintains a portfolio of marketed and investigational vaccines. Walvax is based in Kunming, Yunnan province, and its shares trade on the Shenzhen Stock Exchange under code 300142. Its inclusion is based on proprietary vaccine development rather than distribution or testing services alone.
Company at a glance
Corporate information
- Company entity
- Walvax Biotechnology Co., Ltd.
- Headquarters / principal office
- China
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.walvax.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
SZSE: 300142
vaccine R&D · recombinant proteins · vaccine manufacturing
infectious diseases · preventive medicine
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Walvax Biotechnology is a Chinese biotechnology company specializing in vaccine research, product development, manufacturing and commercialization. Its activities span immunization products and investigation of vaccine technologies for the prevention of infectious disease. The company operates an industrial and research platform in China and maintains a portfolio of marketed and investigational vaccines. Walvax is based in Kunming, Yunnan province, and its shares trade on the Shenzhen Stock Exchange under code 300142. Its inclusion is based on proprietary vaccine development rather than distribution or testing services alone.
Business, technology & evidence
- SecuritiesSZSE: 300142
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Walvax Biotechnology Co., Ltd. ↗Walvax Biotechnology Co., Ltd. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.